Trials / Completed
CompletedNCT03223012
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 116 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
Conditions
- Crohn's Disease
- Ulcerative Colitis (UC)
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis
- Psoriasis
- Ankylosing Spondylitis (AS)
- Non-radiographic Axial Spondyloarthritis
Timeline
- Start date
- 2017-11-15
- Primary completion
- 2019-02-28
- Completion
- 2019-02-28
- First posted
- 2017-07-19
- Last updated
- 2020-02-24
Locations
15 sites across 1 country: Portugal
Source: ClinicalTrials.gov record NCT03223012. Inclusion in this directory is not an endorsement.